---
title: "Resveratrol as an Adjunct to DMARDs in Long-Standing Rheumatoid Arthritis: Effects on Low-Grade In"
id: "medrxiv-12-complementary-use-of-resveratrol-improves-low-grade-chronic-inflammation"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-12-complementary-use-of-resveratrol-improves-low-grade-chronic-inflammation"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.24.26358846v1?rss=1"
published_at: "2026-07-27T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Resveratrol as an Adjunct to DMARDs in Long-Standing Rheumatoid Arthritis: Effects on Low-Grade In
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-12-complementary-use-of-resveratrol-improves-low-grade-chronic-inflammation
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.24.26358846v1?rss=1)
- **Published At:** 2026-07-27T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study evaluated whether the polyphenol **resveratrol** can complement combination **DMARD** therapy in patients with long-duration **rheumatoid arthritis** (RA) by modulating inflammatory cytokines and the JNK–IRS–Akt insulin signaling axis. - Authors enrolled early and late RA patients, assessed clinical disease activity, vascular/atherosclerotic markers, and ex vivo peripheral blood mononuclear cell (PBMC) responses. - PBMCs were isolated for cytotoxicity testing and treated with resveratrol; downstream effects were measured by ELISA and Western blot. - Longitudinal follow-up showed significant first-year improvement in disease activity and atherosclerotic markers, correlated with methotrexate dose. - Comparison of early versus longstanding RA revealed higher circulating cytokines and enhanced **JNK**-mediated stress signaling in chronic disease. - Resveratrol maintained PBMC viability, reduced LPS-induced TNFα and adipokine levels, and downregulated phosphorylated JNK (pJNK) and GSKβ, indicating selective anti-inflammatory modulation. - Effects of resveratrol appeared independent of Akt activation, suggesting targeted inhibition of the **JNK** pathway rather than broad Akt-mediated changes. - Authors conclude chronic RA shows persistent inflammatory and metabolic dysregulation driven by **JNK–NF-κB** activation; resveratrol corrected adipokine imbalance and reduced cytokines ex vivo, supporting potential adjunctive therapeutic value alongside DMARDs. - The report is a preprint (not peer reviewed). Ethical approval, informed consent, and ICMR funding were declared; all data are available within the manuscript or on request.
## Clinical Analysis & Structured Key Points
Complementary Use of Resveratrol Improves Low-Grade Chronic Inflammation Unresolved by Standard DMARD Therapy in Rheumatoid Arthritis | medRxiv Skip to main content Complementary Use of Resveratrol Improves Low-Grade Chronic Inflammation Unresolved by Standard DMARD Therapy in Rheumatoid Arthritis View ORCID Profile Aharna Guin , View ORCID Profile Sanchaita Misra , Dipanjan Bhattacharjee , Sudipta Chatterjee , View ORCID Profile Alakendu Ghosh doi: https://doi.org/10.64898/2026.07.24.26358846 Aharna Guin 1 Institute of Postgraduate Medical Education and Research, SSKM Hospital, Kolkata.; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Aharna Guin For correspondence: aharnaguin4{at}gmail.com Sanchaita Misra 2 Institute of Postgraduate Medical Education and Research, SSKM Hospital, Kolkata; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sanchaita Misra Dipanjan Bhattacharjee 2 Institute of Postgraduate Medical Education and Research, SSKM Hospital, Kolkata; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sudipta Chatterjee 2 Institute of Postgraduate Medical Education and Research, SSKM Hospital, Kolkata; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alakendu Ghosh 3 1. Institute of Postgraduate Medical Education and Research, SSKM Hospital, Kolkata. 2.Department of Neuro-Rheumatology, Institute of Neurosciences, Kolkata Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Alakendu Ghosh Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Chronic lowgrade inflammation in long standing rheumatoid arthritis (RA) contributes not only to joint damage but also to metabolic dysregulation, endothelial dysfunction, and elevated cardiovascular (CV) risk. Although combination disease modifying anti rheumatic drugs (DMARDs) remain the mainstay of therapy, their long term efficacy in controlling systemic inflammation and preventing metabolic complications appears limited. Phytochemicals such as resveratrol, a polyphenolic compound widely used in traditional and complementary medicine, possess anti inflammatory and immunomodulatory properties. Objectives: To investigate whether resveratrol can complement the immunomodulatory effects of combination DMARDs in long duration RA patients by modulating inflammatory cytokines and the JNK−IRS−Akt insulin signaling axis. Methods: This study enrolled early and late rheumatoid arthritis patients to assess disease activity, vascular markers, and ex vivo PBMC responses. PBMCs were isolated for cytotoxicity testing and resveratrol treatment, followed by ELISA and Western blot analysis. Statistical comparisons evaluated immunomodulatory effects and alterations in inflammatory signaling. Results: Longitudinal follow up of RA patients showed significant first year improvement in disease activity and atherosclerotic markers, correlated with MTX dose. An early versus late RA comparison revealed elevated cytokines and enhanced JNK mediated stress signaling in longstanding disease. Resveratrol maintained PBMC viability, reduced LPS induced TNF&alpha and adipokine levels, and downregulated pJNK and GSK&beta, indicating targeted anti inflammatory modulation independent of Akt activation. Conclusion: Chronic RA showed persistent inflammatory and metabolic dysregulation driven by JNK−NF&kappaB activation. Resveratrol reduced cytokines, corrected adipokine imbalance, and selectively inhibited JNK, suggesting adjunct therapeutic value alongside DMARDs for improving immunometabolic disturbances in long-standing RA. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Written informed consent was taken from all study participants. The study protocol had been approved by the institutional ethics committee of Institute of Post Graduate Medical Education & Research, Kolkata, and has been performed in accordance with the ethical standards as laid down in ICMR Ethical Guidelines 2006. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present work are contained in the manuscript and are available upon reasonable request to the authors Funder Information Declared Indian Council of Medical Research (ICMR), Government of India Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted July 27, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Complementary Use of Resveratrol Improves Low-Grade Chronic Inflammation Unresolved by Standard DMARD Therapy in Rheumatoid Arthritis Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Complementary Use of Resveratrol Improves Low-Grade Chronic Inflammation Unresolved by Standard DMARD Therapy in Rheumatoid Arthritis Aharna Guin , Sanchaita Misra , Dipanjan Bhattacharjee , Sudipta Chatterjee , Alakendu Ghosh medRxiv 2026.07.24.26358846; doi: https://doi.org/10.64898/2026.07.24.26358846 Share This Article: Copy Citation Tools Complementary Use of Resveratrol Improves Low-Grade Chronic Inflammation Unresolved by Standard DMARD Therapy in Rheumatoid Arthritis Aharna Guin , Sanchaita Misra , Dipanjan Bhattacharjee , Sudipta Chatterjee , Alakendu Ghosh medRxiv 2026.07.24.26358846; doi: https://doi.org/10.64898/2026.07.24.26358846 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Rheumatology Subject Areas All Articles Addiction Medicine (592) Allergy and Immunology (883) Anesthesia (321) Cardiovascular Medicine (4655) Dentistry and Oral Medicine (465) Dermatology (400) Emergency Medicine (629) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1582) Epidemiology (15601) Forensic Medicine (32) Gastroenterology (1167) Genetic and Genomic Medicine (6859) Geriatric Medicine (708) Health Economics (1029) Health Informatics (4826) Health Policy (1407) Health Systems and Quality Improvement (1686) Hematology (567) HIV/AIDS (1298) Infectious Diseases (except HIV/AIDS) (16129) Intensive Care and Critical Care Medicine (1138) Medical Education (647) Medical Ethics (148) Nephrology (702) Neurology (6990) Nursing (357) Nutrition (1053) Obstetrics and Gynecology (1202) Occupational and Environmental Health (985) Oncology (3492) Ophthalmology (1011) Orthopedics (381) Otolaryngology (431) Pain Medicine (452) Palliative Medicine (135) Pathology (691) Pediatrics (1747) Pharmacology and Therapeutics (720) Primary Care Research (747) Psychiatry and Clinical Psychology (5698) Public and Global Health (9514) Radiology and Imaging (2314) Rehabilitation Medicine and Physical Therapy (1402) Respiratory Medicine (1225) Rheumatology (620) Sexual and Reproductive Health (751) Sports Medicine (564) Surgery (748) Toxicology (105) Transplantation (296) Urology (276)
## Related Clinical Research

- [SGLT2 Inhibitors and Rheumatoid Arthritis Risk in Type 2 Diabetes: Summary of Reported Emulated Ta](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-the-association-between-sglt2-inhibitors-and-rheumatoid-arthritis-risk-in-type.md)
- [Lifestyle Changes May Help Prevent Multimorbidity In Prediabetes](https://medichelpline.com/clinical-feed/medical-news-today-23-diet-weight-loss-and-150-minutes-of-exercise-may-protect-against-chronic.md)
- [Ultrasound‑pretreated enzymatic extraction of soluble dietary fiber from orange peel by-products](https://medichelpline.com/clinical-feed/plos-one-14-valorization-of-orange-peel-by-products-via-ultrasound-pretreated-enzymatic.md)
- [Humanitarian Settings Need More Medical Research, Not Less](https://medichelpline.com/clinical-feed/plos-medicine-0-world-humanitarian-day-why-humanitarian-settings-need-more-research-not-less.md)
- [Keto Diet Shows Superior Metabolic Benefits Over Mediterranean and Low-Fat Diets](https://medichelpline.com/clinical-feed/medical-news-today-1-keto-diet-may-have-metabolic-advantages-over-mediterranean-low-fat-diets.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.